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The etiology of colorectal cancer (CRC) has been
linked to deficiencies in mismatch repair and adeno-
matous polyposis coli (APC) proteins, diet, inflamma-
tory processes, and gut microbiota. However, the
mechanism throughwhich themicrobiota synergizes
with these etiologic factors to promote CRC is not
clear. We report that altering the microbiota compo-
sition reduces CRC in APCMin/+MSH2/ mice, and
that a diet reduced in carbohydrates phenocopies
this effect. Gut microbes did not induce CRC in these
mice through an inflammatory response or the pro-
duction of DNA mutagens but rather by providing
carbohydrate-derived metabolites such as buty-
rate that fuel hyperproliferation of MSH2/ colon
epithelial cells. Further, we provide evidence that
the mismatch repair pathway has a role in regulating
b-catenin activity and modulating the differentiation
of transit-amplifying cells in the colon. These data
thereby provide an explanation for the interaction
between microbiota, diet, and mismatch repair defi-
ciency in CRC induction.
INTRODUCTION
Colorectal cancer (CRC) is associated with numerous genetic
changes. Some of the most frequently affected genes are
the adenomatous polyposis coli (APC) gene (Groden et al.,
1991) and genes involved in DNAmismatch repair (MMR) (Leach288 Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc.et al., 1993; Poulogiannis et al., 2010). APC is a tumor suppressor
that is involved in diverse physiological roles and regulates Wnt
signaling by controlling the levels of b-catenin (Senda et al.,
2007). Mutation in or inactivation (via silencing) of MMR genes,
such as MutS homolog 2 (MSH2) and MutL homolog 1 (MLH1),
are the most common lesions in hereditary nonpolyposis colo-
rectal cancer (HNPCC or Lynch Syndrome) and occur in 20%
of sporadic CRC (Poulogiannis et al., 2010); 56% of CRC tumors
that are defective for MMR also harbor APC mutations (Poulo-
giannis et al., 2010). MMR is a multifunctional DNA-repair
pathway that corrects errors arising during DNA replication and
maintains the fidelity of the genome through othermeans (Jiricny,
2006). Based on the known roles of the MMR pathway, it is un-
clear why MMR deficiency predisposes to CRC more so than to
other cancers, suggesting a unique interaction between MMR
genes within colon epithelial cells and the cell’s environment.
The intestinal microbiota has been identified as a key contrib-
utor to the development of CRC (Arthur and Jobin, 2011; Arthur
et al., 2012; Barthold and Jonas, 1977; Chen et al., 2008; Griven-
nikov et al., 2012; Huber et al., 2012; Klein et al., 1977; Wu et al.,
2009). Many of these studies highlight the role of inflammation in
producing a niche for specific microbes to elicit their oncogenic
effects (Arthur et al., 2012; Chen et al., 2008; Grivennikov et al.,
2012; Huber et al., 2012). However, since the etiology of most
CRCs does not have an inflammatory component (Grivennikov
et al., 2012), it is unclear whether these recent findings can
be extrapolated to the development of other types of CRC.
Another etiologic factor that contributes to CRC development
is a ‘‘western diet’’ (Magalha˜es et al., 2012; Miller et al., 2010).
Dietary glycemic load and total carbohydrate intake have also
been implicated in CRC development in some studies (France-
schi et al., 2001; Gnagnarella et al., 2008; Meyerhardt et al.,
2012). Notably, a comprehensive meta-analysis found a positive
association of total carbohydrate intake with CRC (Gnagnarella
et al., 2008), and a recent prospective study showed that carbo-
hydrate intake was associated with an increased risk of recur-
rence of CRC (Meyerhardt et al., 2012). However, it remains
unclear how themicrobiota and diet affect CRC and how their ef-
fects intersect with host genetics and with other known etiologic
factors to promote CRC.
The APCMin/+ (multiple intestinal neoplasia) mouse is a well-
established animal model of human adenomatous polyposis
(Moser et al., 1990). These mice spontaneously develop multiple
polyps in the small intestine and colon. Combining the APCMin/+
mutation with MSH2 deficiency results in a large increase in
polyp numbers (Reitmair et al., 1996). Although the enhanced
mutation frequency associated with MMR deficiency might
lead to mutation in genes involved in regulating the Wnt-b-cate-
nin axis (Reitmair et al., 1996; Sohn et al., 2003), mutations in
these genes are expected to be rare and might not explain the
pronounced synergistic effect of theMSH2 and APCMin mutation
on tumor formation. As the etiology of HNPCC is associated with
aggressive and rapid adenoma development, it is critical to un-
derstand how major environmental factors such as microbiota
and diet interact with the MSH2/ genotype and whether these
affect disease progression.
Polyp incidence is not reduced in germ-free APCMin/+ mice
(Dove et al., 1997), indicating that gut microbes have little to
no role in disease progression in this background. Here we
investigated whether gut microbiota and diet have the capacity
to affect polyp formation in an APCMin/+MSH2/ mouse model
of CRC. We found that altering the microbiota composition
with oral antibiotics dramatically reduced CRC specifically
in APCMin/+MSH2/ mice. We also demonstrated that a diet
reduced in carbohydrates can phenocopy this effect and show
that gut microbes stimulated CRC development through the pro-
duction of carbohydrate-derived metabolites such as butyrate.
Furthermore, we show that MSH2 and MLH1 deficiency led to
enhanced b-catenin activity and cellular hyperproliferation in
colon epithelial cells, and this activity was dependent on gut
microbes. These data thereby provide an explanation for the
puzzling link between MMR deficiency and CRC and implicate
both diet and gut microbiota in disease pathogenesis.
RESULTS
Gut Microbiota Induce Polyps in APCMin/+MSH2/Mice
To gain insight into the mechanism of CRC development, we
manipulated four knowncomponents—Apc andMsh2mutations,
the microbiota, and diet—separately and in combination and
measured their effects on polyp numbers in mice. We used
mice bearing the APCMin/+ (Su et al., 1992) and MSH2/ muta-
tions. To measure the contribution of the microbiota, we altered
gut bacterial community structure with antibiotics (ampicillin
metronidazole,neomycin, andvancomycin),whichwereprovided
to the mice through their drinking water continuously in utero to
6 weeks post-birth. Mice on the antibiotic cocktail exhibited an
10,000-fold reduction of colonic bacteria (Figure 1A and Fig-
ure S1A available online) and had enlarged cecums (Figure S1B),
but their bodyweights were normal (Figure S1C). Ampicillin alonereduced bacterial load by 1,000-fold, whereas metronidazole
did not (Figure 1A). The composition of the microbiota was
strongly affected in both the metronidazole- and ampicillin-
treated mice (Figures 1A, 1B, and S1D). Antibiotic-cocktail treat-
ment had little to no effect on polyp numbers in APCMin/+
MSH2+/ mice at 3, 6 (Figures 1C and 1D), and 12 weeks of age
(Figures S1E and S1F), supporting a previous report (Dove et al.,
1997). Combining the APC mutation with the MSH2/ mutation
led toa large increase in thenumberofpolyps in thesmall intestine
and colon (Figures 1C and 1D) as previously observed (Reitmair
et al., 1996). A 16S rRNA gene-based microbiota sequencing
analysis showed that the microbial composition was similar be-
tween the APCMin/+MSH2+/ and APCMin/+MSH2/ genotypes
(Figures 1B and S1D), indicating that the increased polyp count
in APCMin/+MSH2/micewas not due to differences inmicrobial
composition. Antibiotic-cocktail treatment only had amarginal ef-
fect on polyp numbers in APCMin/+MSH2/ mice at 3 weeks of
age (Figures 1C and 1D). However, at 6 weeks of age, antibiotic
treatment led to an2 and an6-fold reduction in polyp numbers
in the small intestines and colons of APCMin/+MSH2/ mice,
respectively (Figures1Cand1D). Treatmentwith singleantibiotics
(ampicillin or metronidazole) led to reduced polyp numbers in the
colons of APCMin/+MSH2/ mice but not in the small intestines
(Figures 1C and 1D).
We graded the polyps according to established histopatho-
logical criteria (Figure S1G). This analysis showed that compared
to untreated mice, antibiotic-cocktail-treated APCMin/+MSH2/
mice had fewer grade 1 toR 3 polyps in both the small intestine
and colon (Figures 1E and 1F). Metronidazole and ampicillin also
reduced grade 1 to R 3 polyps but only in the colon (Figure 1F
and data not shown). The fact that antibiotic treatment led to a
reduction in grade 1 polyps, which include aberrant crypt foci,
argues that gut microbiota in APCMin/+MSH2/ mice act at an
early stage in the formation of CRC, perhaps even as a tumor
initiator. Moreover, that metronidazole treatment reduced polyp
numbers without affecting total bacterial abundance indicates
that not all members of the gut microbiota contribute equally to
CRC development in this animal model.
CRC Development in APCMin/+MSH2/ Mice Is
Independent of Microbial-Driven Inflammation or DNA
Damage
Recent reports highlight the role of inflammatory cells, including
specific lymphocyte subsets, and the gut microbiota in promot-
ing CRC (Allen et al., 2012; Arthur et al., 2012; Chen et al., 2008;
Grivennikov et al., 2012; Huber et al., 2012). However, the influ-
ence of gut microbes on CRC development is likely not through
an inflammatory response in this APCMin/+MSH2/ mouse
model. First, the composition of the inflammatory cell compo-
nent of the lamina propria was within normal limits in all geno-
types and treatments (Figure 2A). Second, neutrophils and
plasma cell numbers did not vary between the two genotypes
(Figure 2B), including IFNg-positive Th1 cells (Figure 2C). Third,
the numbers of Treg and Th17 cells, which influence colitis-asso-
ciated CRC (Grivennikov et al., 2012; Huber et al., 2012), were
similar between the different genotypes and treatments (Figures
2D and 2E). Fourth, polyp numbers were not reduced in APCMin/+
MSH2/ mice that were RAG1 deficient (Figure 2F), indicatingCell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc. 289
Figure 1. Intestinal Bacteria Influence
Tumor Growth in APCMin/+MSH2/ Mice
(A) Total bacterial content was estimated by
measuring the abundance of 16S rRNA gene
copies/g sample, collected from the colons of
APCMin/+MSH2+/mice that were either untreated
(Untreat) or treated with the antibiotic cocktail
(Abx), ampicillin (Amp), metronidazole (Metro), and
7% low-carbohydrate diet (7% LC).
(B) Principal components analysis of 16S rRNA
gene-sequencing analysis of gut microbes ob-
tained from the indicated mice and treatments.
PC1 and PC2 explain 24.14% and 18.24% of
variation, respectively.
(C and D) Polyp count in 3- and 6-week-
old APCMin/+MSH2+/ (A+/M+/) and APCMin/+
MSH2/ (A+/M/) mice untreated and treated
with the indicated oral antibiotics in the small in-
testine and colon, respectively.
(E and F) Pathology scores of 6-week-old mice for
polyps observed in the small intestine and colon,
respectively.
The data were analyzed by the Mann-Whitney
test, n R 14. See also Figure S1.that lymphocytes do not enhance CRC in APCMin/+MSH2/
mice. Fifth, ablating either the inflammasome through caspase-
1 deletion or NOD1/2 signaling through RIP2 deletion does not
alter polyp numbers in this mousemodel (Figures 2G and 2H) un-
like in colitis-associatedmodels of CRC (Chen et al., 2008; Huber
et al., 2012). Hence, these genetic manipulations could not reca-
pitulate the 6-fold reduction of colonic polyps that was achieved
with antibiotic treatment.
MSH2 is a central component of MMR (Jiricny, 2006).
Inasmuch as our results showed that reduction of the gut micro-
biota decreased CRC in APCMin/+MSH2/ hosts, we hypothe-
sized that antibiotics reduced the occurrence of mutations by
mitigating the mutagenic effects of the microbiota (Wang et al.,
2008). Thus, we used the lacI-containing transgenic mouse mu-
tation detection system to measure the mutation frequency in
colonic epithelial cells. We found that there was an increase in
the mutation frequency in colon epithelial cells from MSH2/
mice compared to MSH2+/mice (Figure S2A), as expected (Jir-
icny, 2006). However, the mutation frequencies were similar be-
tween colon epithelial cells from untreated or antibiotic-treated290 Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc.MSH2/ mice (Figure S2A). Further-
more, antibiotic treatment did not reduce
the mutation frequency in adenomas iso-
lated from APCMin/+MSH2/ mice (Fig-
ure S2B). Because some DNA mutagens
causeDNAbreaks in the absence of point
mutations, we assessed whether gH2AX
levels, a cellular marker for double-
stranded DNA (dsDNA) breaks, were
affected by antibiotics or the genotype.
However, we found that gH2AX levels
did not vary between genotypes and
treatments and were >10-fold lower
than in irradiated colon epithelial cells(Figure S2C), suggesting that microbiota did not induce dsDNA
breaks in APCMin/+MSH2/ mice. Taken together, these data
suggest that gut microbiota induce CRC through a mechanism
that is independent of both inflammation and DNA damage.
A Diet Reduced in Carbohydrates Can Phenocopy
Microbial Depletion
Our results show that polyp development in the colons of
APCMin/+MSH2/mice is dependent on gut microbiota particu-
larly between weeks 3 and 6 after birth (Figure 1D), correspond-
ing to the time when mice are weaned. Owing to the enormous
metabolic potential of the gut microbiota, we hypothesized that
gut microbesmight contribute to CRC development by providing
diet-derived metabolites that facilitate tumor initiation and/or
progression. Given that carbohydrates have been implicated in
CRC, we tested whether carbohydrate-derived metabolites
were associated with CRC. Three-week-old APCMin/+MSH2/
mice were given a normal or low-carbohydrate diet (Table S1).
Approximately 58% of the calories provided with the normal
diet derived from carbohydrates, compared to 7% for the
Figure 2. No Discernible Role for Inflammation in CRC Development
in APCMin/+MSH2/ Mice
(A) Inflammatory scores for the mucosa in the colon.
(B) Quantification of polymorphonuclear leukocytes (PMN) and plasma cells
(PC) per high-powered field (HPF) in histological sections of colonic tissue of
the indicated mice, nR 7.
(C) Quantification by flow cytometry of lamina propria IFNg Th1 cells within
colonic tissue of the indicated mice.
(D and E) Quantitation by flow cytometry of Tregs (D) and Th17 (E) lamina
propria lymphocytes are reported, n = 4.
(F–H) Polyp counts in the small intestines and colons of 6-week-old
APCMin/+MSH2/RAG1+/ (A+/M/R1+/) and APCMin/+MSH2/RAG1/
(A+/M/R1/) mice (F), APCMin/+MSH2/Caspase-1+/ (A+/M/C+/) and
APCMin/+MSH2/Caspase-1/ (A+/M/C/) mice (G), and APCMin/+
MSH2/RIP2+/ (A+/M/Rp+/) and APCMin/+MSH2/RIP2/
(A+/M/Rp/) mice (H).
The data were analyzed by the Mann-Whitney test.
Figure 3. Carbohydrate-Derived Metabolites Drive CRC Develop-
ment in APCMin/+MSH2/ Mice
(A) The body weights of A+/M/ mice (8 per group) were fed normal diets
(ND) with or without tributyrin (TriB) or 7% low-carbohydrate diet (7% LC) from
week 3 to week 6.
(B and C) Polyp count was measured for the small intestines and colons of
mice treated with an antibiotic cocktail (Abx: ampicillin, metronidazole, and
neomycin) and/or 7% LC diets from weeks 3 to 6.
The data were analyzed by the Mann-Whitney test.low-carbohydrate diet. Weight gain was normal with the low-car-
bohydrate diet (Figure 3A), indicating that mice on this diet were
not under caloric restriction. The low-carbohydrate diet did not
alter the total bacterial abundance (Figure 1A) but led to substan-
tial changes in the microbial communities (Figures 1B and S1D).Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc. 291
Figure 4. Gut Microbiota Induce Colonic
Epithelial Cell Proliferation and Polyp Devel-
opment in APCMin/+MSH2/ Mice
(A) Colonic epithelial cells derived from mice with
the indicated treatments were collected, and the
% DNA breaks were measured by the alkaline
comet assay. Figures S2D–S2F show typical data
for identifying breaks. Each symbol represents an
individual mouse.
(B) The % of colon epithelial cells from indicated
genotypes/treatments showing a greater than
2N DNA, as measured by propidium iodide (PI)
staining.
(C) Ki-67 expression in the distal colon for the
indicated mice. Magnification is 203.
(D) The fraction of cells in the distal colon ex-
pressing Ki-67 as a function of the total length of
each crypt. Each symbol represents the mean
fraction of Ki-67 expression for multiple crypts for
each individual mouse (derived from Figure S3A).
(E) Ki-67-positive cells per crypt in the proximal
and distal colon for the indicated mice (n R 3)
under various treatments.
(F) Colonic epithelial cells were stained with an-
nexin V and PI, and the % apoptosis was esti-
mated by flow cytometry (n = 6 per group).
The data in (A) and (D) were analyzed by theMann-
Whitney test.Strikingly, the low-carbohydrate diet reduced polyp numbers in
the small intestines and colons of APCMin/+MSH2/ mice (Fig-
ures 3B and 3C). By comparison, treating mice with antibiotics
from weeks 3 to 6 produced a similar decrease in polyp number
(Figures 3B and 3C). Furthermore, there was no additive effect
on polyp number by combining the low-carbohydrate diet
and the antibiotic treatment (Figures 3B and 3C) suggesting
that both treatments function by the same mechanism. Taken
together, these data indicate that carbohydrate-derived me-
tabolites produced by gut microbes drive CRC development in
APCMin/+MSH2/ mice.
Hyperproliferation of MSH2-Deficient Intestinal
Epithelial Cells Is Dependent on Gut Microbiota and
Dietary Carbohydrates
We next assessed whether microbial-derived metabolites
influence colon epithelial proliferation particularly in APCMin/+
MSH2/ mice. We used the comet assay because it detects
both ssDNA and dsDNA breaks and can be used to detect repli-
cation-derived breaks (Olive and Durand, 2005). Figures S2D–
S2F show typical experimental results of the comet assays that
were used to calculate the fraction of cells with DNA breaks
(Figure 4A). Such results revealed that colon epithelial cells
harvested from APCMin/+MSH2/ mice had approximately two
times the number of cells with DNA breaks as cells harvested
from APCMin/+MSH2+/ mice. Interestingly, antibiotic treatment
or a low-carbohydrate diet reduced the number of cells with
DNA breaks in APCMin/+MSH2/ mice (Figure 4A). These DNA
breaks are likely ssDNA breaks given that our previous analysis292 Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc.did not show elevated levels of dsDNA breaks (i.e., gH2AX) in
APCMin/+MSH2/ mice (Figure S2C). Furthermore, we found
that 12% of colon epithelial cells in APCMin/+MSH2/ mice
were in the S-G2-M phases of the cell cycle compared to 8%
in APCMin/+MSH2+/ mice (Figure 4B). We also measured
expression of the nuclear protein Ki-67, which does not stain
cells in G0, in colon epithelial cells. Strikingly, Ki-67 expression
was elevated in the distal colons of APCMin/+MSH2/mice rela-
tive to controls, and antibiotics or a low-carbohydrate diet
reduced Ki-67 expression in these mice (Figures 4C, 4D, and
S3A). Furthermore, the increased Ki-67 expression in APCMin/+
MSH2/mice occurred specifically in the distal region of the co-
lons in APCMin/+MSH2/ mice (Figure 4E), which is noteworthy
because >90% of polyps in the colon of APCMin/+MSH2/mice
occur in the distal region of the colon. Ki-67-positive cells were
also increased in MSH2/ mice compared to their wild-type
(WT) controls (Figure 4D), indicating that MSH2 deficiency alone
is associated with abnormal cellular proliferation. We also
observed an increase in apoptosis in colon epithelial cells from
APCMin/+MSH2/ mice compared to controls, but not in antibi-
otic-treated APCMin/+MSH2/mice (Figure 4F). Taken together,
these data show that APCMin/+MSH2/ colonic epithelial cells
hyperproliferate relative to controls, which is dependent on gut
microbiota and dietary carbohydrates.
To further investigate the nature of the hyperproliferation
phenotype observed in MSH2-deficient colonic epithelial cells,
we assessed the status of the Wnt/b-catenin signaling pathway,
which regulates the proliferation and differentiation of intestinal
epithelial cells within the crypts (Fevr et al., 2007; Pinto et al.,
Figure 5. Elevated b-Catenin Activity in MSH2/ and APCMin/+MSH2/ Mice
(A) Immunohistochemistry analysis for b-catenin expression of colons frommice of the indicated treatments and genotypes. Representative figures are depicted,
with figures from other mice shown in Figure S4A. Arrows identify cells with nuclear b-catenin expression. Magnification is 1003.
(B) Same as (A) except that b-catenin was visualized by immunofluorescence. Right panels are representative confocal images of colonic crypts (magnification
633). Boxes within the left panels are magnified and shown on the right panels.
(C) cDNA levels were quantified by qPCR for b-catenin, and downstream targets of b-catenin (Lgr5, CD44, EphB2, EphB3). Data are normalized to HPRT cDNA
levels. cDNA levels for another house-keeping gene, Tata-box binding protein (TBP), are also shown.2003). In APCMin/+MSH2+/ mice, b-catenin was present in a
normal membrane pattern and localized to the nucleus of the
cells at the crypt base (Figures 5A, 5B, and S4A). In contrast,
accumulation of nuclear b-catenin was observed in colonic
epithelial cells that were located above the first third of the crypt
of APCMin/+MSH2/ colons (Figures 5A, 5B, and S4A). This
defect was also observed in MSH2/ mice, indicating that the
APCMin mutation does not lead to aberrant b-catenin localization
(Figure S4B). Antibiotic treatment and the low-carbohydrate diet
restored the nuclear b-catenin expression in APCMin/+MSH2/
mice to that seen in APCMin/+MSH2+/ mice (Figures 5A and
S4A). b-catenin transcript levels were also elevated in MSH2/
colonic epithelial cells compared to controls (Figure 5C). These
results correlate well with the expression of Ki-67 (Figure 4), sug-
gesting that enhanced b-catenin activity drives hyperprolifera-
tion of MSH2/ colonic epithelial cells. Furthermore, we found
that the expression of c-MYC protein, which is a downstreamtarget of b-catenin, was elevated beyond the normal proliferative
zone in APCMin/+MSH2/mice (Figure S4C). Other downstream
targets of b-catenin, such as stem cell markers Lgr5, CD44,
EphB2, and EphB3 (Herr et al., 1990), were also elevated at the
transcript level in MSH2/ colonic epithelial cells compared to
controls (Figure 5C). Hence, the enhanced b-catenin activity de-
fines these cells as actively proliferating and undifferentiated.
Indeed, the APCMin/+MSH2/ colonic crypts were character-
ized by reduction in expression levels of p21(Cip1/WAF1), a protein
that governs cell-cycle arrest and differentiation (Figure S4D). By
comparison, p21(Cip1/WAF1) expression was lost in an adenoma-
tous polyp (Figure S4E). Therefore, the abnormal b-catenin activ-
ity in MSH2/ and APCMin/+MSH2/ colonic crypts probably
leads to expansion of the proliferating/undifferentiated compart-
ment likely consisting of transit-amplifying cells. Strikingly, gut
microbes had the capacity to modulate b-catenin activity spe-
cifically in the colon of MSH2/ hosts, and reduction of gutCell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc. 293
microbiota or dietary carbohydrates normalized the proliferation
and differentiation phenotype to levels observed in controls.
Mice Deficient in MLH1 or in the ATPase Activity of
MSH2 Have Enhanced b-Catenin Activity and
Hyperproliferation of Colon Epithelial Cells
In addition to repairing mismatched base pairs, theMMR system
also induces apoptosis through the DNA damage response
(DDR) and inhibits recombination between nonidentical se-
quences (Jiricny, 2006). However, it is unclear which of these
functions are responsible for suppressing polyp formation, hy-
perproliferation, and aberrant b-catenin activity in colon epithe-
lial cells. MSH2/ mice are deficient in all functions of MMR;
however, MSH2G674D/G674D mice are active for DDR but cannot
carry out other functions of MMR (Kucherlapati et al., 2010).
We also assessed whether MLH1/ mice, which are defective
in both DNA repair and DDR and are mutated for a gene
(MLH1) that is frequently inactivated in CRC, are similar to
MSH2/mice with respect to the phenotypes that are reported
in this study. Indeed, increased polyp numbers were observed in
MLH1/ (as previously reported in Shoemaker et al., 2000) and
MSH2G674D/G674D mice on the APCMin/+ background (Figures
S5A and S5B).We found that colon epithelial cells fromMLH1/
and MSH2G674D/G674D mice displayed a hyperproliferative
phenotype (Figures S5C and S5D). Further, we observed
increased nuclear b-catenin in MLH1/ and MSH2G674D/G674D
mice relative to controls (Figure S5E) and found increased
expression of downstream targets of b-catenin in MLH1/
mice (Figure S5F), indicative of increased b-catenin activity.
These data indicate that deregulated b-catenin and hyperprolif-
eration are general properties in MMR-mutated colon epithelial
cells and that MMR’s role inmismatch repair and/or homologous
recombination sensitizes colon epithelial cells to transformation
by microbial-derived metabolites.
Butyrate Induces Aberrant Proliferation and
Transformation of Colon Epithelial Cells
The fact that reducing either gut microbiota or dietary carbohy-
drates resulted in the reduction in both Ki-67 and b-catenin
expression in APCMin/+MSH2/ mice led us to hypothesize
that bacterial metabolites might fuel the aberrant hyperprolifera-
tion of colon epithelial cells in these mice. We analyzed the colon
contents from mice subjected to either a low-carbohydrate diet
or metronidazole treatment because these treatments did not
impact total bacterial load (Figure 1A) but had an impact on polyp
numbers (Figures 1D and 2C). Using two analytical platforms
(i.e., NMR and direct flow injection/liquid chromatography-tan-
dem mass spectrometry [DI/LC-MS/MS]), we found that mice
under these treatments exhibited a reduction in numerous
metabolites (Figure S6). Using other methodologies, we also
measured the levels of lactate and short-chain fatty acids
(SCFAs), which are major carbohydrate-derived metabolites
that are produced by microbial fermentation. We found that
cocktail antibiotics or a low-carbohydrate diet reduced the levels
of mucosal lactate in these mice (Figure 6A); however, metroni-
dazole did not (Figure S6). On the other hand, the only SCFA
that was statistically reduced by all antibiotic treatments and
by the low-carbohydrate diet was butyrate (Figures 6B and294 Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc.S7B). Although butyrate functions as a histone deacetylase
inhibitor (HDACi) at high concentrations (Donohoe et al., 2011,
2012a), the concentration of butyrate that is produced by
gut bacteria in the distal colon, the part of the colon that ex-
hibits the hyperproliferation phenotype and amasses polyps in
APCMin/+MSH2/ mice, promotes epithelial cell proliferation
(Donohoe et al., 2012a). In addition, butyrate modulates canon-
ical Wnt signaling (Lazarova et al., 2004) and has been shown in
some studies to promote CRC (Freeman, 1986; Lupton, 2004).
Hence, we focused our efforts on the microbial-derived metab-
olite butyrate in subsequent experiments.
Butyrate is produced by specific members of Firmicutes
(Louis and Flint, 2009), and it was notable that metronidazole
and the low-carbohydrate diet reduced the phylum Firmicutes
without impacting total bacterial abundance (Figures 1A and
S1D). Specifically, these treatments led to the reduction of
three families within Firmicutes, namely Clostridiaceae, Lachno-
spiraceae, and Ruminococcaceae (Figure 6C), that are known
to produce butyrate (Van den Abbeele et al., 2013). Represen-
tatives of genus Coprococcus and Roseburia, which belong to
Lachnospiraceae and are members of the Clostridium cluster
XIVa (Pryde et al., 2002), and Anaerotruncus, which belong
to Ruminococcaceae and cluster IV (Louis and Flint, 2009),
were also reduced by these treatments as measured by pro-
portion of sequencing reads (Figure 6C) and by quantitative
PCR (qPCR) (Figure 6D). In addition, the gene copy number
for butyryl-CoA transferase, a microbial gene responsible for
butyrate production, was also reduced by these treatments
(Figure 6E).
To test whether butyrate directly affects polyp formation
in APCMin/+MSH2/ mice, antibiotic-treated mice were fed a
diet enriched in tributyrin, a stable form of butyrate that breaks
down into three butyrate molecules in the gastrointestinal tract
(Donohoe et al., 2012b). Tributyrin led to a large increase in buty-
rate levels in the small intestine (Figure S7C). Strikingly, tributyrin
stimulated both polyp numbers (Figure 7A) and epithelial cell
proliferation (Figures 7B and S3B) in the small intestines of anti-
biotic-treated APCMin/+MSH2/ mice. However, tributyrin had
no effect on polyp number or cellular proliferation in the colon
(Figures 7C, 7D, and S3C), which was likely due to an insufficient
increase of butyrate in the colon in tributyrin-fed mice (Fig-
ure S7C). Hence, we administered sodium butyrate directly in
the colons of antibiotic-cocktail treated mice by rectal instilla-
tion. This experiment revealed that 50 mM and 0.5 mM of sodium
butyrate, which represent concentrations of butyrate found in the
distal part of the colon (Donohoe et al., 2012a), stimulated prolif-
eration of colon epithelial cells in APCMin/+MSH2/mice but not
in controls (Figures 7E–7G and S3D). In contrast, consistent with
its action as an HDACi, high concentrations of sodium butyrate
(i.e., 10 and 100 mM) did not increase colon epithelial cell prolif-
eration in APCMin/+MSH2/ mice (Figures 7E–7G and S3D).
These data show that butyrate facilitates the aberrant hyperpro-
liferation phenotype of colon epithelial cells in APCMin/+MSH2/
mice.
Collectively, these results indicate that the gut microbiota
plays a key role in CRC by providing metabolites such as buty-
rate that ‘‘fuel’’ the transformation of APCMin/+MSH2/ colonic
epithelial cells.
Figure 6. Antibiotic and Low-Carbohydrate Diets Impact Butyrate
Levels
(A) Lactate imaging inmouse colon samples. Left panel shows the hematoxylin
and eosin (H&E)-stained samples (above) and the bioluminescence imaging of
lactate (bottom). Right panel depicts the relative lactate contents measured in
the colon samples from treated APCMin/+MSH2/ mice.
(B) The levels of butyrate (and other SCFAs; see Figure S7A) were
measured in the small intestines and colons from mice under indicated
treatments.
(C) Comparison of the abundance of specific bacteria in the colon of indicated
treatments shown as proportion of reads. Data are derived from the 16S rRNA
gene-sequencing analysis, n = 7.
(D) The abundance of clostridium cluster IV and XIVa under indicated treat-
ments was measured by qPCR using 16S rRNA gene primers specific for each
species, nR 2.DISCUSSION
Carbohydrates account for about 50% of the daily intake of
adults receiving a western-style diet, with starch and sucrose
as the largest components (Roy et al., 2006). Previous studies
have linked carbohydrate-rich diets to CRC in humans (France-
schi et al., 2001; Gnagnarella et al., 2008; Meyerhardt et al.,
2012), although a mechanistic insight into this relationship is
lacking. Our study supports the carbohydrate-cancer link by
showing that a diet reduced in carbohydrates resulted in
reduced polyp formation in APCMin/+MSH2/ mice. Our anal-
ysis revealed that gut microbes stimulated polyp formation by
providing metabolites that stimulated hyperproliferation and
transformation of colon epithelial cells in these mice. Hence, in
a genetic model of CRC, gut microbiota stimulate polyp for-
mation through a mechanism that is distinct from other models
of CRC.
Even though the antibiotic and the low-carbohydrate treat-
ments have differing effects on the microbial communities (Fig-
ure 1B), we cannot exclude the possibility that both treatments
reduced the level of a pathogenic microbe(s) that has a direct
and unknown effect on CRC development. Our findings that
butyrate administration positively correlates with polyp forma-
tion in APCMin/+MSH2/ mice argue for a role of butyrate-pro-
ducing gut microbes in the etiology of CRC. Butyrate has been
shown to have antiproliferative and anticancer properties (Lup-
ton, 2004; Singh et al., 2014), likely through its action as an
HDACi (Marks et al., 2000). However, at lower concentrations,
butyrate stimulates colon epithelial cell proliferation (Donohoe
et al., 2012a, 2012b).Moreover, some studies show that butyrate
stimulates CRC (Freeman, 1986; Lupton, 2004). The discrepancy
on the effects of butyrate on CRC has been termed the ‘‘butyrate
paradox.’’ The major butyrate-producing bacteria belong to
Firmicutes (Van den Abbeele et al., 2013), and we found that
various antibiotic regimens and a diet reduced in carbohydrates
decrease representatives from Firmicutes, including specific
members of Clostridia. Interestingly, Fusobacterium nucleatum
was recently shown to be associated with CRC (Castellarin
et al., 2012; Kostic et al., 2012), and this microbe also produces
abundant levels of butyrate. However, Fusobacterium was not
detected in any of our mice (data not shown), implicating mem-
bers of Clostridia in disease pathology in APCMin/+MSH2/
mice. Microbial-produced lactate was recently shown to induce
hyperproliferation of colon epithelial cells in starved mice, and
we also noted that some of our treatments led to a reduction in
mucosal lactate (Okada et al., 2013). In addition, our metabolo-
mics analysis shows that treatments that reduce CRC correlate
with substantial changes in lumenal metabolites. Our work
does not discount a role for some of these metabolites in dis-
ease pathology. We propose that gut microbes stimulate CRC
by providing metabolites such as butyrate that drive the aber-
rant proliferation/b-catenin activity of APCMin/+MSH2/ colonic
epithelial cells.(E) The abundance of butyryl CoA-transferase gene relative to RNA polymer-
ase B gene under indicated treatments was measured by qPCR, nR 3.
The data in (C) were analyzed by the Mann-Whitney test.
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Figure 7. Microbiota-Derived Metabolite
Butyrate Drives Colon Epithelial Cell Hyper-
proliferation and in APCMin/+MSH2/ Mice
(A and C) Polyp numbers in the small intestines
and colons of tributyrin-fed APCMin/+MSH2/
mice compared to the polyps in the untreated and
antibiotic-treated mice (from Figures 3B and 3C).
(B and D) Ki-67 expression in the small intestines
and colons of tributyrin-fed mice (see also Figures
S3B and S3C).
(E) Mice with indicated genotypes were treated
with cocktail antibiotics for 3 weeks, then rectally
administered PBS or sodium butyrate for 24 hr,
and Ki-67 expression was measured in colon
epithelial cells by immunohistochemistry.
(F and G) The fraction of cells in the distal colon
expressing Ki-67 as a function of the total length of
each crypt from APCMin/+MSH2+/ (F) or APCMin/+
MSH2/ mice (G). Each symbol represents
the mean fraction of Ki-67 expression for mul-
tiple crypts for each individual mouse. See also
Figure S3D.
The data in (A)–(D) were analyzed by Mann-
Whitney test.The expression and activity of b-catenin are precisely regu-
lated to create a gradient that defines the fate of intestinal epithe-
lial cells (Bordonaro et al., 2008). Several dietary factors can
modify b-catenin activity (Tarapore et al., 2012). Between them,
butyrate has been shown to modulate canonical Wnt signaling,
and depending on the status of b-catenin activity, colon epithelial
cells respond differently to butyrate (Lazarova et al., 2004). In
normal colonic epithelium, butyrate is themajor source of energy
(Roediger, 1980) and synergizes with low levels of Wnt signaling
to facilitate normal growth and proliferation. However, MSH2-
deficient colon epithelial cells havederegulated b-catenin activity
and likely have a different response tomicrobial-derived butyrate
that might result in increased proliferation and apoptosis.
In this report, we found that MSH2 and MLH1 deficiency
leads to a hyperproliferative phenotype of colon epithelial cells.
Although components of the MMR system can induce cell-cycle
arrest in response to extensive DNA damage (Jiricny, 2006), we
did not find evidence that the microbiota produce genotoxic
agents in this animal model (Figure S2). Indeed, the DDR function
of MSH2 is not involved in the hyperproliferative property of co-
lon epithelial cells (Figure S2). Instead, this defect is likely due to
the aberrant activation of b-catenin signaling in MSH2/ cells296 Cell 158, 288–299, July 17, 2014 ª2014 Elsevier Inc.given that b-catenin regulates colon
epithelial cell proliferation (Gregorieff
et al., 2005). Notably, overexpression of
both b-catenin and c-MYC occurred in
all crypts in MSH2- and MLH1-deficient
mice in an APC-independent manner,
suggesting that MMR proteins have
a direct role in modulating b-catenin
signaling rather than by, for example,
suppressing mutations in this pathway
(Liu et al., 2000), which would be ex-
pected to lead to sporadic overexpres-sion of b-catenin in some but not all crypts. On the other hand,
the increased proliferation of colon epithelial cells in MMR
mutant mice could be due to a defect in differentiation from
transit-amplifying (proliferating) cells to terminally differentiated
(nonproliferating) cells. Indeed, the expanded proliferating cells
in MMR mutant colons were positive for b-catenin and c-MYC
expression (pro-proliferative) and negative for p21(Cip1/WAF1),
which induces cell-cycle inhibition and differentiation of colonic
epithelium (van de Wetering et al., 2002), supporting the notion
that MMR deficiency leads to an expanded transit-amplifying
cell population. In fact, endoplasmic reticulum stress has been
identified as a differentiation signal for stem cells (Heijmans
et al., 2013), and it is conceivable that genetic stress that is
sensed by MMR during the rapidly proliferating transit-ampli-
fying cell stage might have a similar effect. Regardless of the
mechanism, because deregulated b-catenin signaling is a
marker of early neoplastic changes of intestinal epithelium (Van
der Flier et al., 2007), our results suggest that MSH2-deficient
colonic epithelial cells are highly predisposed to transformation.
Greater than 10%of all CRCs in humans harbor lesions in both
APC and MMR genes (Poulogiannis et al., 2010), and 1/15 in-
dividuals will get CRC in their lifetime in the western world. By
providing a direct link between host genetics and gut microbes,
our findings suggest that a diet reduced in carbohydrates as well
as alterations in the intestinal microbial community could be




All mice in this study were on the C57BL/6J background. MSH2+/mice were
provided by T. Mak (Toronto). APCMin/+ mice were obtained from The Jackson
Laboratories. The genotyping for APCMin/+ and for MSH2/ were described
previously (Dietrich et al., 1993; Peters et al., 2003). RAG1/ (Jackson
Labs), caspase-1/, and RIP2/ mice (R. Flavell; Yale) were raised under
specific pathogen-free conditions. Teklad Global 18% protein rodent diet
(Harlan, WI, USA) constituted the normal diet. The basal diet 5755 purchased
from TestDiet was also used and produced similar results to the Teklad diet
with respect to polyp numbers. The 7% low-carbohydrate diet was made
from 590N and Teklad global 18% protein diet. These diets were administered
after weaning. A breakdown of the macronutrients in the diets is shown in
Table S1. Tributyrin-fortified diet was prepared from Teklad global 18% diet
supplemented with 6% tributyrin (Sigma).
Antibiotic Treatment
Pregnant mice were treated with 1 g/l ampicillin, 1 g/l metronidazole, 1 g/l
neomycin, and 0.5 g/l vancomycin in their drinking water, which was replaced
daily for the first 2 weeks, then every 2 days until the mice were 6 weeks old or
12 weeks old (Figure 1). Mice were also treated with 1 g/l ampicillin or 1 g/l
metronidazole alone as described above.
16S rRNA Gene Analysis of Bacteria
16S rRNA sequencing was performed on an Illumina MiSeq2 using V2 chem-
istry by fully sequencing the V5-V7 16S rRNA gene region amplified using bar-
coded primers previously optimized for Serial Illumina Sequencing. See the
Extended Experimental Procedures for further information.
Immunohistochemistry
Frozen sections of Swiss-rolled colons were examined by immunohistochem-
istry and immunofluorescence with anti-b-catenin antibody (Abcam). Staining
was performed with corresponding rabbit primary antibodies followed by
secondary goat anti-rabbit antibody conjugated with HRP or FITC (Southern
Biotech).
qPCR for b-Catenin and Target Genes
Oligonucleotide primers used to amplify b-catenin and target genes are shown
in Table S2.
Measurement of SCFAs
SCFA was measured by gas chromatography from stool samples after micro-
filtration and vacuum distillation as described previously (Fernandes et al.,
2011). See the Extended Experimental Procedures for further information.
Statistical Analysis
The data were analyzed using the Mann-Whitney and the two-tailed Student’s
t tests. *p < 0.05, **p < 0.01, and ***p < 0.001. All error bars represent SD.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2014.04.051.
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